In response to injury, hemodynamic changes, or neurohormonal activation, the heart
undergoes a series of structural and functional changes that have been termed cardiac …

Objective: To evaluate the use of existing practice control groups in randomized controlled
trials of behavioral interventions and the role of extrinsic health care services in the design …

Objectives: This analysis aimed to perform a head-to-head comparison of 3 of the promising
biomarkers of cardiovascular (CV) outcomes in heart failure (HF)—soluble ST2 (sST2) …

Objectives: The aim of this study was to evaluate whether chronic heart failure (HF) therapy
guided by concentrations of amino-terminal pro–B-type natriuretic peptide (NT-proBNP) is …

Properly Multinational Study2 and the Pro-BNP Investigation of Dyspnea in the Emergency
Department7 showed that NP levels were more accurate for diagnosis or exclusion of ADHF …

The natriuretic peptides are important tools to establish diagnosis and prognosis in heart
failure (HF). With application of therapies for HF, changes in both B-type natriuretic peptide …

Background—Concentrations of soluble (s) ST2 predict prognosis in heart failure. We
recently found changing doses of β-blocker (BB) may affect sST2 concentrations. It remains …

Objective Despite previous research that focused on liver transaminases as predictors of
cardiovascular disease, there has been limited research evaluating the predictive value of …

Aims Galectin‐3 is a prognostic heart failure (HF) biomarker that may mediate cardiac
fibrosis. We examined the value of serial galectin‐3 measurement for prognosis and …

Understanding of chronic heart failure (HF) has progressed from a syndrome of disordered
hemodynamics caused by alterations in the structure of the heart to one that involves …